Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.

Ping-Han HuangHsiao-Han TsaiBo-Hung LiaoYi-Ling LinJia-Tsrong JanMi-Hua TaoYu-Chi ChouChe-Ming Jack HuHui-Wen Chen

Published in: Human vaccines & immunotherapeutics (2020)

A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.

Keyphrases

sars cov
respiratory syndrome coronavirus
binding protein
dengue virus
type diabetes
high throughput
transcription factor
protein protein
wild type